Panjon Ltd
Incorporated in 1983, Panjon Ltd manufactures and trades in consumers and pharmaceutical
products[1]
- Market Cap ₹ 40.6 Cr.
- Current Price ₹ 23.6
- High / Low ₹ 30.0 / 16.1
- Stock P/E 53.4
- Book Value ₹ 9.88
- Dividend Yield 0.00 %
- ROCE 4.00 %
- ROE 2.55 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Debtor days have improved from 61.7 to 39.1 days.
- Company's working capital requirements have reduced from 267 days to 105 days
Cons
- Company has a low return on equity of 3.17% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.29 | 19.47 | 12.26 | 13.98 | 20.10 | 25.94 | 26.43 | 14.49 | 8.41 | 6.09 | 12.55 | 30.46 | 49.34 | |
| 19.15 | 22.54 | 12.35 | 14.00 | 19.68 | 25.63 | 26.11 | 14.30 | 12.45 | 6.09 | 12.57 | 29.83 | 48.29 | |
| Operating Profit | 0.14 | -3.07 | -0.09 | -0.02 | 0.42 | 0.31 | 0.32 | 0.19 | -4.04 | 0.00 | -0.02 | 0.63 | 1.05 |
| OPM % | 0.73% | -15.77% | -0.73% | -0.14% | 2.09% | 1.20% | 1.21% | 1.31% | -48.04% | 0.00% | -0.16% | 2.07% | 2.13% |
| 0.02 | -1.51 | 0.43 | 0.52 | 0.21 | 0.36 | 0.29 | 0.33 | 0.30 | 0.38 | 0.45 | 0.31 | 0.18 | |
| Interest | 0.00 | 0.00 | 0.17 | 0.19 | 0.28 | 0.24 | 0.15 | 0.10 | 0.07 | 0.05 | 0.06 | 0.18 | 0.23 |
| Depreciation | 0.08 | 0.13 | 0.14 | 0.13 | 0.11 | 0.15 | 0.27 | 0.23 | 0.20 | 0.21 | 0.22 | 0.23 | 0.24 |
| Profit before tax | 0.08 | -4.71 | 0.03 | 0.18 | 0.24 | 0.28 | 0.19 | 0.19 | -4.01 | 0.12 | 0.15 | 0.53 | 0.76 |
| Tax % | 312.50% | -27.18% | -1,133.33% | 33.33% | 50.00% | 53.57% | 115.79% | 47.37% | 3.49% | -575.00% | 0.00% | 24.53% | |
| -0.17 | -3.43 | 0.36 | 0.12 | 0.12 | 0.14 | -0.03 | 0.10 | -4.15 | 0.81 | 0.15 | 0.40 | 0.76 | |
| EPS in Rs | -0.11 | -2.21 | 0.23 | 0.08 | 0.08 | 0.09 | -0.02 | 0.06 | -2.68 | 0.52 | 0.09 | 0.23 | 0.44 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 3% |
| 3 Years: | 54% |
| TTM: | 126% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 73% |
| 3 Years: | 28% |
| TTM: | 117% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 18% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -4% |
| 3 Years: | 3% |
| Last Year: | 3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.50 | 15.50 | 15.50 | 15.50 | 15.50 | 15.50 | 15.50 | 15.50 | 15.50 | 15.50 | 16.31 | 17.17 | 17.17 |
| Reserves | 8.85 | 0.52 | 0.89 | 1.00 | 1.13 | 1.27 | 1.23 | 1.31 | -2.84 | -2.02 | -1.46 | -0.62 | -0.21 |
| 1.67 | 1.52 | 1.41 | 1.26 | 1.89 | 1.84 | 1.56 | 1.33 | 0.81 | 0.78 | 1.44 | 2.65 | 3.55 | |
| 1.39 | 0.51 | 0.24 | 0.28 | 0.29 | 0.34 | 0.92 | 1.12 | 0.58 | 0.64 | 1.10 | 0.85 | 1.02 | |
| Total Liabilities | 27.41 | 18.05 | 18.04 | 18.04 | 18.81 | 18.95 | 19.21 | 19.26 | 14.05 | 14.90 | 17.39 | 20.05 | 21.53 |
| 5.69 | 0.92 | 0.84 | 0.74 | 0.72 | 0.87 | 1.12 | 0.96 | 0.95 | 0.91 | 0.90 | 1.09 | 1.24 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.18 | 1.08 | 1.08 | 1.08 | 1.09 | 1.09 | 1.08 | 1.07 | 1.07 | 1.08 | 1.08 | 1.10 | 1.10 |
| 20.54 | 16.05 | 16.12 | 16.22 | 17.00 | 16.99 | 17.01 | 17.23 | 12.03 | 12.91 | 15.41 | 17.86 | 19.19 | |
| Total Assets | 27.41 | 18.05 | 18.04 | 18.04 | 18.81 | 18.95 | 19.21 | 19.26 | 14.05 | 14.90 | 17.39 | 20.05 | 21.53 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.48 | 0.89 | -0.20 | 0.18 | -0.17 | 0.49 | 0.35 | 0.34 | 1.82 | 0.04 | -0.42 | -4.34 | |
| -0.10 | 4.74 | -0.06 | -0.04 | -0.08 | -0.31 | -0.51 | -0.06 | -0.19 | -0.19 | -0.21 | -0.44 | |
| 3.44 | -5.14 | -0.19 | -0.17 | 0.40 | -0.05 | -0.07 | -0.24 | -0.51 | 0.18 | 1.88 | 2.50 | |
| Net Cash Flow | -0.14 | 0.49 | -0.44 | -0.03 | 0.15 | 0.13 | -0.22 | 0.04 | 1.12 | 0.04 | 1.25 | -2.27 |
| Free Cash Flow | -3.58 | 5.54 | -0.26 | 0.14 | -0.25 | 0.18 | -0.17 | 0.27 | 1.63 | -0.14 | -0.62 | -4.76 |
| CFO/OP | -2,471% | -29% | 222% | -1,100% | -29% | 177% | 122% | 195% | -45% | 2,100% | -689% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 241.44 | 184.28 | 261.39 | 21.67 | 16.89 | 23.64 | 45.57 | 93.45 | 26.47 | 93.50 | 52.64 | 39.06 |
| Inventory Days | 117.88 | 46.16 | 101.43 | 95.13 | 66.63 | 57.65 | 59.10 | 120.11 | 306.47 | 610.67 | 152.35 | 65.87 |
| Days Payable | 12.18 | 7.20 | 4.14 | 2.93 | 2.19 | 3.98 | 11.48 | 28.24 | 19.51 | 63.17 | 6.93 | 3.56 |
| Cash Conversion Cycle | 347.14 | 223.24 | 358.68 | 113.87 | 81.33 | 77.31 | 93.20 | 185.32 | 313.43 | 641.00 | 198.07 | 101.37 |
| Working Capital Days | 336.43 | 262.83 | 428.41 | 177.80 | 123.85 | 112.85 | 138.51 | 261.22 | 277.76 | 480.07 | 216.38 | 105.45 |
| ROCE % | 0.33% | -14.51% | 1.13% | 2.08% | 2.87% | 2.80% | 1.84% | 1.59% | -24.93% | 1.23% | 1.37% | 4.00% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacturing Sales INR Hundreds |
|
||||||||||
| Trading Sales INR Hundreds |
|||||||||||
| Number of Permanent Employees Number |
|||||||||||
| Trade Receivables Turnover Ratio Percentage |
|||||||||||
| Geography-wise Revenue: Central INR Hundreds |
|||||||||||
| Geography-wise Revenue: West INR Hundreds |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
4 Apr - ENCLOSED HEREWITH RTA CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DP) REGULATIONS, 2018
- Closure of Trading Window 25 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Feb - ENCLOSED HEREWITH UNAUDITED FINACIAL RESULT FOR THE QUARTER ENDED 31/12/2025 IN NEWSPAPER
-
Board Meeting Outcome for BOARD MEETING DATED 13/02/2026
13 Feb - Approved Q3/9M results; 8,97,706 warrants lapsed; 25% subscription forfeited; limited review dated 13-Feb-2026.
-
UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 31/12/2025
13 Feb - Approved unaudited financial results for quarter and nine months ended 31 Dec 2025; board met 13 Feb 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
a) Panjon is in the business of specialized Medicinal, Digestive, Ayurvedic & Confectionary products
b) Presently, the company is mainly into reality development
c) The company, considering the slowdown in the reality sector and considering the experiences of the promoters, has started the trading business of Petroleum product. The turnover is mainly
from the trading activities of the petroleum products.
d) The company also started venturing into
the waste management activities of medical
bi-products.